Telara pharma
WebSee Telara Pharma funding rounds, investors, investments, exits and more. Evaluate their financials based on Telara Pharma's post-money valuation and revenue. WebSolution – Telara Pharma. We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies.
Telara pharma
Did you know?
WebApr 15, 2024 · Telara Pharma is focused on the research, development, and marketing of drugs for the treatment of high prevalence pathologies (mainly kidney injuries and … WebApr 15, 2024 · TORONTO, April 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has entered into an exclusive worldwide license agreement with Telara Pharma of Spain (“Telara”) to clinically develop and market cilastatin, a small-molecule drug candidate for …
WebTelara Pharma is actively using 39 technologies for its website, according to BuiltWith. These include Viewport Meta, IPhone / Mobile Compatible, and SSL by Default. UNLOCK PREMIUM DATA WITH DATABOOST Unlock even more features with Crunchbase Pro . Start Your Free Trial . WebApr 15, 2024 · Arch Biopartners is a clinical stage company developing new drug candidates for treating organ damage caused by inflammationNovel Mechanism of Action - selective dipeptidase-1 antagonists that... March 8, 2024
WebUna spin-off para el proyecto Cilastatina, el primer nefroprotector del mundo descubierto por el fallecido Dr. Tejedor y su equipo WebTelara Pharma has designed a drug capable of preventing acute kidney injury. Headquarters Location Madrid, Spain Suggest an edit Missing: Telara Pharma 's …
WebApr 15, 2024 · AP NEWS . Listen. Sections
WebContact – Telara Pharma. We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. lowest emiision power souceWebApr 15, 2024 · (2024-04-15 TSXV:ARCH) Arch Biopartners Enters Into Worldwide License Agreement With Telara Pharma To Re-Purpose Cilastatin For The Treatment And … jams restaurant menu shelby twpWebTelara Pharma – Developing therapeutic solutions for the prevention and treatment of kidney disease and sepsis. We use cookies on our website to give you the most relevant … Acute kidney Injury (AKI) is a syndrome that results in a sudden decrease in kidney … Cilastatin: a potential treatment strategy against COVID-19 that may decrease … Telara Pharma awarded at the 8th IiSGM Research and Innovation Conference … Telara Pharma S.L. is a spin-off company from the Gregorio Marañón Health … Great! Thank you for you message! We will get back to you real soon. With the creation of Telara Pharma to try to bring cilastatin into clinical use, we … Company (referred to as either “the Company”, “We”, “Us” or “Our” in this … Telara Pharma S.L. has been created in Madrid (Spain), acquiring a license … jams project officeWebMay 11, 2024 · Telara Pharma is funded by GENESIS Biomed. Funding Rounds Number of Funding Rounds 1 Total Funding Amount €100K Telara Pharma has raised a total of €100K in funding over 1 round. This was a Seed round raised on May 11, 2024. Which funding types raised the most money? How much funding has this organization raised over time? … jamspublishing.wordpress.comWeb--Arch Biopartners Inc., announced today it has entered into an exclusive worldwide license agreement with Telara Pharma of Spain to clinically develop and market cilastatin, a small-molecule drug ... jams reference numberWebTelara Pharma raised a total of $120K. Who are the investors of Telara Pharma? Investors of Telara Pharma include Genesis Biomed and Gregorio Marañón Hospital. Who to Watch P Predictit PredictIt is a real-money political prediction market, a stock market for politics. lowest emf monitorsWebApr 15, 2024 · Arch Biopartners ( OTCQB:ACHFF) announces that it has entered into an exclusive worldwide license agreement with Telara Pharma of Spain to clinically develop … lowest emf smartphones